8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.
2010 / Randomized crossover trial
Twenty-five patients with early AMD were randomly assigned to oral saffron (20 mg/d) or placebo for 3 months, then switched to the alternate intervention for another 3 months. After saffron supplementation, fERG amplitudes increased compared with baseline and placebo (mean change after saffron, 0.25 log μV; mean change after placebo, -0.003 log μV; P < 0.01). In addition, fERG thresholds decreased after saffron but not placebo compared with baseline (mean change after saffron, -0.26 log units; mean change after placebo, 0.0003 log units). The authors noted that results need replication and clinical significance remains to be evaluated.
Falsini B, Piccardi M, Minnella A, et al. Invest Ophthalmol Vis Sci, 2010. PMID 20688744
2010 / Randomized controlled trial
In a 16-week randomized, double-blind, placebo-controlled trial, 46 patients with mild to moderate Alzheimer's disease received 30 mg daily of saffron or a placebo. Saffron produced significantly better cognitive outcomes than placebo on the ADAS-cog scale (P = 0.04) and clinical dementia rating (P = 0.04). No significant differences between groups were observed for adverse events.
Akhondzadeh S, Sabet MS, Harirchian MH, et al. J Clin Pharm Ther, 2010. PMID 20831681
2010 / Randomized controlled trial
In a randomized trial, 168 older adults with mild cognitive impairment received daily B vitamins (0.8 mg folic acid, 0.5 mg B12, 20 mg B6) or placebo for 24 months. Brain atrophy averaged 0.76% per year in the active group versus 1.08% with placebo (P = 0.001). The response was greater among individuals with baseline homocysteine above 13 micromol/L, whose atrophy rate dropped by 53% (P = 0.001). Faster atrophy was linked to lower cognitive test scores.
Smith AD, Smith SM, de Jager CA, et al. PLoS One, 2010. PMID 20838622
2009 / Interventional trial
To assess the efficacy of radical scavengers for age-related hearing loss, 46 elderly patients were given oral rebamipide (300 mg/day), alpha-lipoic acid (60 mg/day), and vitamin C (600 mg/day) for at least 8 weeks. Following treatment, hearing levels were significantly improved at all frequencies.
Takumida M, Anniko M Acta Otolaryngol, 2009. PMID 18607930
2009 / Double-blind, parallel-group, placebo-controlled randomized trial
Thirty Japanese men and women aged 50 to 80 with mild cognitive impairment were randomized to take either Yamabushitake (four 250 mg tablets containing 96% dry powder three times daily) or placebo for 16 weeks, followed by 4 weeks of observation. At weeks 8, 12, and 16, the Yamabushitake group showed significantly increased cognitive function scale scores compared with placebo, with scores increasing with duration of intake. However, scores decreased significantly by 4 weeks after terminating intake. Laboratory tests showed no adverse effects.
Mori K, Inatomi S, Ouchi K, et al. Phytother Res, 2009. PMID 18844328
2009 / Randomized controlled trial (subgroup analysis)
Researchers analyzed data from 29,133 Finnish male smokers in the ATBC Study over a median follow-up of 6.1 years (3,571 deaths) to examine if age, smoking, and dietary vitamin C modified the effect of 50 mg/day vitamin E on mortality. Age and dietary vitamin C intake had a second-order interaction with vitamin E supplementation. Among participants with dietary vitamin C intake above the median (90 mg/day), vitamin E increased mortality in those aged 50-62 years by 19% (95% CI: 5, 35) but decreased mortality in those aged 66-69 years by 41% (95% CI: -56, -21). Vitamin E had no effect among participants with vitamin C intake below the median, and smoking quantity did not modify the effect.
Hemilä H, Kaprio J Am J Epidemiol, 2009. PMID 19218294
2009 / Double-blind randomized placebo-controlled trial
A 12-week randomized trial evaluated 93 post-menopausal women receiving either 20 g soy protein with 160 mg total isoflavones or a taste-matched whole milk protein placebo. Eighty-four women completed the study. Women taking isoflavones experienced significant improvements in all four Menopause-specific Quality of Life subscales (vasomotor, psychosexual, physical, and sexual), with no changes in the placebo group. No significant changes occurred within groups for cognition, serum androgens, or plasma lipids, though a group-by-time interaction showed significantly lower total testosterone and HDL levels in the isoflavone group versus placebo at study end.
Basaria S, Wisniewski A, Dupree K, et al. J Endocrinol Invest, 2009. PMID 19411814
2009 / Randomized controlled trial (substudy)
In a substudy of the Women's Antioxidant Cardiovascular Study, 2,824 women aged >=65 years were tested 4 times over 5.4 years to evaluate the effects of vitamin E (402 mg alternate days), beta carotene (50 mg alternate days), and vitamin C (500 mg daily). Vitamin E and beta carotene were not associated with slower rates of cognitive change compared to placebo (mean difference in change: -0.01, 95% CI -0.05 to 0.04, P=0.78 for vitamin E; 0.03, 95% CI -0.02 to 0.07, P=0.28 for beta carotene). Vitamin C was associated with better performance at the final assessment (mean difference 0.13, 95% CI 0.06 to 0.20, P=0.0005) but was not associated with cognitive change over time (mean difference 0.02, 95% CI -0.03 to 0.07, P=0.39).
Kang JH, Cook NR, Manson JE, et al. Circulation, 2009. PMID 19451353
2009 / Randomized controlled trial
Fifty-seven Alzheimer's disease patients were randomized to receive placebo or 800 IU of vitamin E daily for six months, with 33 finishing the trial. Among vitamin E-treated patients, respondents showed lower blood oxidized glutathione (GSSG) levels and maintained cognitive test scores. In non-respondents where oxidative stress was not prevented, cognition decreased sharply to levels lower than those taking placebo.
Lloret A, Badía MC, Mora NJ, et al. J Alzheimers Dis, 2009. PMID 19494439
2009 / Prospective pre-post pilot study
A prospective pilot study examined 30 postmenopausal women treated with 100 mg/day of an isoflavone-rich concentrated soy extract for 6 months, assessing gluteal skin punches before and after. Isoflavone treatment produced a 9.46% increase in epidermal thickness in 23 patients and reduced the papillary index (indicating reduced wrinkling) in 21 women. Dermal collagen increased in 25 women (86.2%), elastic fibers increased in 22 women (75.8%), and dermal blood vessels significantly increased in 21 women.
Accorsi-Neto A, Haidar M, Simões R, et al. Clinics (Sao Paulo), 2009. PMID 19578653
2009 / Randomized, double-blind, placebo-controlled trial
A 90-day randomized, double-blind, placebo-controlled trial evaluated daily administration of the ketogenic compound AC-1202 in 152 patients with mild to moderate Alzheimer's disease who maintained a normal diet. AC-1202 significantly elevated serum beta-hydroxybutyrate 2 hours post-dose. Compared to placebo, AC-1202 led to a significant difference in mean change from baseline in ADAS-Cog score at Day 45 across the ITT (1.9-point difference, p = 0.0235), per-protocol (2.53-point difference, p = 0.0324), and dosage-compliant (2.6-point difference, p = 0.0215) groups. Improvements were most pronounced in APOE4-negative subjects, showing significant ADAS-Cog differences at both Day 45 and Day 90. Adverse events were more frequent with AC-1202, primarily mild-to-moderate and transient gastrointestinal issues.
Henderson ST, Vogel JL, Barr LJ, et al. Nutr Metab (Lond), 2009. PMID 19664276
2009 / Double-blind randomized parallel trial
In a double-blind parallel study, 12 postmenopausal women took 1,000 mg of American ginseng powder daily for 4 months, while 13 took a placebo, with treadmill walking tests conducted before and after supplementation. Ginseng had no effect on heart rate, blood pressure, plasma glucose, or lactate at rest or post-exercise. However, the ginseng group showed higher resting plasma glutathione disulfide (GSSG), a lower GSH:GSSG ratio, lower resting total antioxidant content, and elevated plasma malondialdehyde and urine 8-hydroxydeoxyguanosine. Erythrocyte superoxide dismutase and GSH reductase activities were also increased following ginseng supplementation.
Dickman JR, Koenig RT, Ji LL J Am Coll Nutr, 2009. PMID 19828907
2009 / Randomized controlled trial
In a 30-day trial of 60 healthy adults aged 55 to 72, participants consumed 120 mL daily of standardized Lycium barbarum juice or placebo. The juice group experienced significant increases in lymphocytes, interleukin-2, and immunoglobulin G relative to baseline and placebo. Subjective ratings of general well-being also improved, whereas no changes occurred in natural killer cells, CD4, CD8, or clinical safety markers.
Amagase H, Sun B, Nance DM J Med Food, 2009. PMID 19857084
2008 / Double-blind, randomized, controlled clinical trial
A double-blind trial evaluated the effects of 50 mg daily oral DHEA versus placebo for 1 year in 225 healthy older adults. There were no differences between the DHEA and placebo groups in change over time in cognitive function (P > .10). Over time, BDI scores decreased for men (P = .006) and women (P = .02), and Satisfaction with Life Scale scores increased for women (P = .004), but no differences were observed between the DHEA and placebo groups on these measures, the SF-36, the Life Satisfaction Index-Z scale, or sexual function scales (P > .10).
Kritz-Silverstein D, von Mühlen D, Laughlin GA, et al. J Am Geriatr Soc, 2008. PMID 18482290
2008 / Randomized, double-blind, placebo-controlled crossover trial
Fourteen postmenopausal women completed a randomized, double-blind, placebo-controlled crossover trial receiving 3.5 g/day of powdered Maca and matching placebo for 6 weeks each. No significant differences were observed in serum concentrations of estradiol, FSH, LH, or SHBG between baseline, Maca, and placebo (P > 0.05). However, Maca significantly reduced Greene Climacteric Scale scores for psychological symptoms, including anxiety, depression, and sexual dysfunction compared to baseline and placebo (P < 0.05). Yeast-based assays showed no physiologically significant estrogenic or androgenic activity in Maca extracts.
Brooks NA, Wilcox G, Walker KZ, et al. Menopause, 2008. PMID 18784609
2008 / Pilot clinical trial
A pilot study evaluated 30 men with low-risk prostate cancer asked to adopt comprehensive lifestyle modifications for 3 months. In 24 participants with adequate samples, natural log-transformed telomerase activity was 2.00 at baseline and 2.22 after 3 months (p = 0.031). Increased telomerase activity correlated with lower LDL cholesterol (r = -0.36, p = 0.041) and less psychological distress (r = -0.35, p = 0.047).
Ornish D, Lin J, Daubenmier J, et al. Lancet Oncol, 2008. PMID 18799354
2008 / Comparative clinical trial
Researchers analyzed circulating markers from long-term human studies lasting 1 and 6 years. Severe calorie restriction with adequate nutrition did not change serum IGF-1 or the IGF-1 to IGFBP-3 ratio. In contrast, lowering protein intake from 1.67 to 0.95 g/kg/day for 3 weeks in six calorie-restricted volunteers reduced serum IGF-1 from 194 to 152 ng/mL.
Fontana L, Weiss EP, Villareal DT, et al. Aging Cell, 2008. PMID 18843793
2008 / Repeated-measures controlled dietary intervention
Twenty-three younger and 19 older adults completed three 18-day dietary trials with protein intakes of 0.50, 0.75, and 1.00 g/kg/d. Nitrogen balance was evaluated from days 14 to 17 of each trial to determine individual protein requirements using linear regression. The mean (+/- SD) protein requirement was not different between younger and older subjects (0.61 +/- 0.14 vs. 0.58 +/- 0.12 g/kg/d, respectively). An adequate protein allowance for combined subjects was calculated to be 0.85 +/- 0.21 g/kg/d, which did not differ statistically from the Recommended Dietary Allowance (RDA).
Campbell WW, Johnson CA, McCabe GP, et al. Am J Clin Nutr, 2008. PMID 18996869
2008 / Randomized, placebo-controlled split-face trial
A randomized, placebo-controlled, split-face study evaluated the anti-wrinkle effects of a cosmetic containing 4% niacinamide versus a control cosmetic applied for 8 weeks in 30 healthy Japanese females with eye-area wrinkles. The 4% niacinamide cosmetic demonstrated marked and moderate improvement in 64% of subjects, showing a significant difference compared to the control site (P < 0.001). Wrinkle grades decreased significantly more than baseline (P < 0.001) and control (P < 0.001), and skin roughness (Ra value) reductions were also significantly greater than baseline (P < 0.01) and control (P < 0.05). One subject discontinued due to minimal irritation.
Kawada A, Konishi N, Oiso N, et al. J Dermatol, 2008. PMID 19017042
2008 / Randomized, double-blind, placebo-controlled clinical trial
A randomized, double-blind, placebo-controlled trial evaluated whether 120 mg of Ginkgo biloba extract twice daily reduced incident dementia compared to placebo over a median follow-up of 6.1 years. Overall, 523 participants developed dementia (277 in the G. biloba group and 246 in the placebo group). The hazard ratio for G. biloba compared with placebo was 1.12 (95% CI, 0.94-1.33; P = .21) for all-cause dementia and 1.16 (95% CI, 0.97-1.39; P = .11) for Alzheimer disease. G. biloba also did not alter progression to dementia in participants with mild cognitive impairment (HR, 1.13; 95% CI, 0.85-1.50; P = .39).
DeKosky ST, Williamson JD, Fitzpatrick AL, et al. JAMA, 2008. PMID 19017911
2008 / Clinical trial and in vitro study
Researchers examined the mechanisms of coenzyme Q10 (CoQ10) on UVB-induced wrinkle formation in vitro and in a clinical trial. In vitro, CoQ10 decreased UVB-induced IL-6 production in normal human keratinocytes and significantly decreased MMP-1 production in fibroblasts over 24 hours. In the clinical trial, the use of a 1% CoQ10 cream for five months reduced wrinkle score grade as observed by a dermatologist.
Inui M, Ooe M, Fujii K, et al. Biofactors, 2008. PMID 19096121
2007 / Randomized controlled trial
In a 1-year randomized controlled trial, 149 healthy women aged 70-78 were assigned to resistance training (RES), balance-jumping training (BAL), a combination (COMB), or control (CON). Self-rated physical functioning showed a mean inter-group difference of 10% (95% CI: 0-22%) favoring COMB versus CON. Leg extensor force increased more in RES (14%; 4-25%) and COMB (13%; 3-25%) compared with CON, while dynamic balance improved in BAL (6%; 1-11%) and COMB (8%; 3-12%). There were no inter-group differences in BMC at the proximal femur, but in COMB women training at least twice a week, tibial shaft structure weakened 2% (0-4%) less than in the CON group.
Karinkanta S, Heinonen A, Sievänen H, et al. Osteoporos Int, 2007. PMID 17103296
2007 / Cross-sectional comparison and pre-post exercise intervention
Researchers assessed EPC clonogenic and migratory capacity in 46 healthy sedentary men across three age groups, and in 10 sedentary middle-aged and older men before and after a 3-month aerobic exercise intervention. EPC colony-forming units were approximately 75% lower in middle-aged (12 +/- 3) and older (8 +/- 2) men compared with young men (40 +/- 7, P < 0.01), while migration was reduced in older (453 +/- 72) versus young (813 +/- 114) and middle-aged (760 +/- 114) men. In the intervention group, 3 months of aerobic exercise significantly increased EPC colony-forming units from 10 +/- 3 to 22 +/- 5 and migratory activity from 683 +/- 96 to 1,022 +/- 123 (P < 0.05).
Hoetzer GL, Van Guilder GP, Irmiger HM, et al. J Appl Physiol (1985), 2007. PMID 17158243
2007 / Double-blind randomized placebo-controlled trial
A double-blind trial in the Netherlands randomized 728 older adults with elevated homocysteine to daily oral folic acid (800 microg) or placebo for 3 years. After 3 years, low-frequency hearing thresholds increased by 1.0 dB (95% CI, 0.6 to 1.4 dB) in the folic acid group versus 1.7 dB (CI, 1.3 to 2.1 dB) in the placebo group (difference, -0.7 dB [CI, -1.2 to -0.1 dB]; P = 0.020). Folic acid supplementation did not affect the decline in high-frequency hearing. Limitations include strict homocysteine eligibility criteria and the study taking place in a setting without food folic acid fortification, where baseline folate levels were about half those of the U.S. population.
Durga J, Verhoef P, Anteunis LJ, et al. Ann Intern Med, 2007. PMID 17200216